Evidence map›Paper›PMID 42078432›Full record

ArticleFrontiers in medicine2026

Case Report: Upadacitinib treatment for Behçet's syndrome with intestinal damage.

Ling Yuan, Yingying Sun, Jianjun Yan

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ling Yuan *Department of Dermatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Yingying Sun *Department of Dermatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Jianjun YanDepartment of Dermatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 17-year-old male presenting with recurrent, debilitating oral and genital ulcerations. Diagnostic evaluation confirmed multisystemic Behçet's syndrome with multifocal intestinal involvement. Following the exclusion of infectious contraindications, the patient was initiated on upadacitinib (15 mg daily) as a primary systemic intervention. Remarkable clinical remission of mucocutaneous and gastrointestinal ulcerations was achieved within 1 month. Sustained improvement was observed during subsequent follow-up, suggesting that upadacitinib may serve as an effective therapy for multisystemic Behçet's syndrome in adolescent patients.

Indexed as

Behçet’s syndromeintestinal damageJAK inhibitorsmall molecule drugupadacitinib

Identifiers

PMID42078432
PMCPMC13132688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.